找回密碼
 To register

QQ登錄

只需一步,快速開(kāi)始

掃一掃,訪(fǎng)問(wèn)微社區(qū)

打印 上一主題 下一主題

Titlebook: Coronary Microvascular Dysfunction; Filippo Crea,Gaetano A. Lanza,Paolo G. Camici Book 2014 The Editor(s) (if applicable) and The Author(s

[復(fù)制鏈接]
樓主: Enkephalin
11#
發(fā)表于 2025-3-23 09:43:17 | 只看該作者
Health promotion in the workplace,d myocardial damage in patients undergoing CABG surgery have included ischemic conditioning and drugs, as adenosine and acadesine, diazoxide, volatile anesthetic agents, anti-inflammatory agents, statins and sodium–hydrogen exchange inhibitors. The results achieved with these forms of treatment are discussed in this chapter.
12#
發(fā)表于 2025-3-23 14:58:45 | 只看該作者
ormation on the prevention and treatment of coronary microva.In the past two decades a number of studies have shown that abnormalities in the function and structure of coronary microcirculation can be detected in several cardiovascular diseases.?On the basis of the clinical setting in which it occur
13#
發(fā)表于 2025-3-23 19:35:06 | 只看該作者
14#
發(fā)表于 2025-3-23 23:14:54 | 只看該作者
15#
發(fā)表于 2025-3-24 05:31:48 | 只看該作者
16#
發(fā)表于 2025-3-24 08:06:23 | 只看該作者
17#
發(fā)表于 2025-3-24 14:15:03 | 只看該作者
Treatment of Primary CMDthis chapter. While the pharmacological approach to acute MVA still waits to be defined, treatment of takotsubo disease is mainly based on the control of hemodynamic state, due to the usual spontaneous improvement of the disease.
18#
發(fā)表于 2025-3-24 16:30:22 | 只看該作者
Treatment of CMD in Obstructive CADcluding pharmacological (e.g., adenosine, nitroprusside) and nonpharmacological (e.g., antiembolic devices, ischemic conditioning) tools. This chapter discusses the main results observed with these interventions in these clinical settings.
19#
發(fā)表于 2025-3-24 19:56:12 | 只看該作者
20#
發(fā)表于 2025-3-25 00:34:01 | 只看該作者
Book 2014to the pathogenesis of myocardial ischemia,?thus becoming a possible therapeutic target.?This book provides an update on coronary?physiology?and a systematic assessment of microvascular abnormalities in cardiovascular diseases,?in the hope that it will assist clinicians in prevention, detection?and management of CMD in their everyday activity..
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛(ài)論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國(guó)際 ( 京公網(wǎng)安備110108008328) GMT+8, 2026-1-25 02:53
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
临沧市| 两当县| 应用必备| 灵石县| 遵义县| 铜梁县| 沂源县| 桂阳县| 金乡县| 张家界市| 子长县| 永吉县| 宜丰县| 肥东县| 从江县| 潜山县| 瑞金市| 仲巴县| 翁牛特旗| 石渠县| 东乡| 乌兰浩特市| 奎屯市| 阿荣旗| 临沧市| 沙雅县| 高碑店市| 衡阳市| 沾益县| 隆尧县| 利辛县| 全南县| 巴东县| 雅安市| 永登县| 荃湾区| 喀什市| 盐津县| 措美县| 遂宁市| 剑阁县|